Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free EIKN Stock Alerts

Eikon Therapeutics (EIKN) Competitors

$11.05 +0.72 (+7.00%)
Closing price 03:59 PM Eastern
Extended Trading
$11.04 -0.01 (-0.12%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

EIKN vs. SLS, BHVN, STOK, AUPH, and SEPN

Should you buy Eikon Therapeutics stock or one of its competitors? Eikon Therapeutics's main competitors and comparable companies include SELLAS Life Sciences Group (SLS), Biohaven (BHVN), Stoke Therapeutics (STOK), Aurinia Pharmaceuticals (AUPH), and Septerna (SEPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eikon Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 21.67%. Eikon Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 126.18%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

Eikon Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -43.49% -39.90%
Eikon Therapeutics N/A N/A N/A

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.23N/A
Eikon TherapeuticsN/AN/A-$324.25M-$2.46N/A

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 13 mentions for SELLAS Life Sciences Group and 9 mentions for Eikon Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.51 beat Eikon Therapeutics' score of 0.03 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Eikon Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

SELLAS Life Sciences Group and Eikon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Eikon Therapeutics' return on equity of 0.00% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -1,070.80% -132.67%
Eikon Therapeutics N/A N/A N/A

In the previous week, Eikon Therapeutics had 1 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for Eikon Therapeutics and 8 mentions for Biohaven. Biohaven's average media sentiment score of 0.31 beat Eikon Therapeutics' score of 0.03 indicating that Biohaven is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biohaven
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eikon Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biohaven currently has a consensus price target of $21.75, indicating a potential upside of 48.33%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 126.18%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
2 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.65
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiohavenN/AN/A-$738.82M-$4.64N/A
Eikon TherapeuticsN/AN/A-$324.25M-$2.46N/A

88.8% of Biohaven shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Biohaven beats Eikon Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Eikon Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Eikon Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Eikon Therapeutics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics-753.60% -59.36% -51.46%
Eikon Therapeutics N/A N/A N/A

Stoke Therapeutics has higher revenue and earnings than Eikon Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$184.42M10.95-$6.89M-$3.34N/A
Eikon TherapeuticsN/AN/A-$324.25M-$2.46N/A

Stoke Therapeutics currently has a consensus price target of $43.00, suggesting a potential upside of 37.35%. Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 126.18%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, Eikon Therapeutics had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 9 mentions for Eikon Therapeutics and 6 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.78 beat Eikon Therapeutics' score of 0.03 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eikon Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Eikon Therapeutics beats Stoke Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Eikon Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Eikon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals100.84% 26.11% 19.89%
Eikon Therapeutics N/A N/A N/A

Aurinia Pharmaceuticals currently has a consensus target price of $17.67, suggesting a potential upside of 14.27%. Eikon Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 126.18%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.17
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Eikon Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Eikon Therapeutics and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.48 beat Eikon Therapeutics' score of 0.03 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurinia Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eikon Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$311.51M6.60$287.20M$2.296.75
Eikon TherapeuticsN/AN/A-$324.25M-$2.46N/A

Summary

Aurinia Pharmaceuticals beats Eikon Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Eikon Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Eikon Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Eikon Therapeutics' return on equity of 0.00% beat Septerna's return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-24.51% -9.59% -6.22%
Eikon Therapeutics N/A N/A N/A

Septerna presently has a consensus price target of $51.33, indicating a potential upside of 14.93%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 126.18%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

Septerna has higher revenue and earnings than Eikon Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M45.37-$48.88M-$0.54N/A
Eikon TherapeuticsN/AN/A-$324.25M-$2.46N/A

In the previous week, Septerna had 24 more articles in the media than Eikon Therapeutics. MarketBeat recorded 33 mentions for Septerna and 9 mentions for Eikon Therapeutics. Septerna's average media sentiment score of 0.62 beat Eikon Therapeutics' score of 0.03 indicating that Septerna is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
6 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Eikon Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Septerna beats Eikon Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EIKN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EIKN vs. The Competition

Export
MetricEikon TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$598.41M$3.71B$6.98B$13.04B
Dividend YieldN/A3.76%2.58%10.72%
P/E Ratio-4.4910.55269.5625.30
Price / SalesN/A1,293.72598.74101.64
Price / CashN/A103.0170.5350.75
Price / BookN/A17.5113.086.33
Net Income-$324.25M-$13.32M$3.45B$347.70M
7 Day Performance18.98%1.72%1.11%1.06%
1 Month Performance8.47%1.60%1.79%1.03%
1 Year PerformanceN/A56.45%67.70%20.73%

Eikon Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EIKN
Eikon Therapeutics
2.4056 of 5 stars		$11.05
+7.0%		$25.00
+126.2%		N/A$598.41MN/AN/A384
SLS
SELLAS Life Sciences Group
0.6532 of 5 stars		$10.96
-0.8%		$10.00
-8.7%		+700.0%$2.15BN/AN/A10
BHVN
Biohaven
3.518 of 5 stars		$14.19
-2.4%		$21.63
+52.4%		+3.2%$2.14BN/AN/A239
STOK
Stoke Therapeutics
2.8904 of 5 stars		$32.18
-0.2%		$43.00
+33.6%		+85.2%$2.08B$184.42MN/A100
AUPH
Aurinia Pharmaceuticals
3.5811 of 5 stars		$15.49
+0.3%		$17.67
+14.1%		+26.4%$2.06B$311.51M6.76300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel